Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Segment Information - Additional Information (Details)

v3.25.0.1
Segment Information - Additional Information (Details)
€ in Thousands
 12 Months Ended
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Customer
Disclosure of operating segments [line items]      
Number of external customers exceeded 10% group's revenue | Customer     0
Revenue € 1,104,036 € 1,085,354 € 983,680
External Customers      
Disclosure of operating segments [line items]      
Revenue 1,104,036 1,085,354 983,680
Biopharmaceutical and Diagnostic Solutions | Operating Segments      
Disclosure of operating segments [line items]      
Revenue 937,779 881,337 801,237
Biopharmaceutical and Diagnostic Solutions | Operating Segments | External Customers      
Disclosure of operating segments [line items]      
Revenue 933,742 879,288 799,652
Engineering | Operating Segments      
Disclosure of operating segments [line items]      
Revenue 357,636 372,807 299,500
Engineering | Operating Segments | External Customers      
Disclosure of operating segments [line items]      
Revenue 170,294 206,066 184,028
Total Segments | Operating Segments      
Disclosure of operating segments [line items]      
Revenue 1,295,415 1,254,144 1,100,737
Total Segments | Operating Segments | External Customers      
Disclosure of operating segments [line items]      
Revenue € 1,104,036 € 1,085,354 € 983,680
Total Segments | Operating Segments | Customer      
Disclosure of operating segments [line items]      
Percentage of revenue 10.30% 11.40%  
Revenue € 113,200 € 123,600